Related to Late-Stage Study Results Show Dynavax’ HBV Vaccine Is Better at Protecting Diabetics than Engerix-B

• Dynavax and GSK Choose Clinical Candidate from Endosomal TLR Inhibitor Program
  
• GSK and Crucell Team Up to Develop a Prime-Boost Malaria Vaccine
  
• Investigators Find Pathway that May Better Explain How Antidiabetics Like Avandia Work
  
• Nabi Scores Another $8M from GSK under MRSA Vaccine Deal
  
• GSK Obtains Rights to Delphi’s Antibiotic-Free Tech for Recombinant Vaccines
  
• FDA Significantly Restricts Access to GSK’s Antidiabetic Avandia
  
• Phase III Data Leads Intercell to Shelve Late-Stage Traveler’s Diarrhea Vaccine Patch
  
• AFFiRiS Receives €3.5M from GSK with Preclinical Success in Alzheimer Vaccine Alliance
  
• Compass and Arecor to Develop Heat-Stable Hepatitis B Vaccine
  
• Aduro BioTech Wins $250K in SBIR Grants and Contract with UNM for Vaccine Development
  
• Gilead and GlobeImmune Ally to Develop HBV Vaccine for Use in Combination with Viread
  
• GSK Taps Alnylam’s RNAi Technology for Vaccine Production
  
• Agenus Expands QS-21 Adjuvant License with GSK for $9M
  
• GSK Confirms £500M Investment in Manufacturing Across Multiple U.K. Sites
  
• FDA Approves GSK’s MenHibrix Meningitis Vaccine
  
• GSK Taps Liquidia for Nanoparticle Development
  
• Flu Vaccine Manufacturing Gets Shot in Arm
  
• GSK Teams with GlycoVaxyn on New Bacterial Vaccines
  
• EU Gives Dynavax’ German Manufacturing Plant the Nod for Commercial Production of HBV Vaccine
  
• FDA Lifts Hold on Dynavax’ Phase III HBV Vaccine